About PhRMA

Who We Are

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer and healthier lives. PhRMA is committed to advancing public policies in the United States and around the world that support innovative medical research and progress for patients, ensure innovative medicines are accessible and affordable for patients and provide hope for the treatments and cures of tomorrow.

Membership Criteria

The lifeblood of health care is research and discovery. That’s why in 2017 PhRMA adopted a bold new commitment to the research and development (R&D) of new treatments and cures for patients.

To be eligible for membership in our association, companies must:

- Have a three-year average global R&D to global sales ratio of 10% or greater, and
- Have a three-year average global R&D spending of at least $200 million per year

Most PhRMA member companies far exceed this threshold, investing in total more than $102.3 billion in R&D in 2021 - the highest level of investment on record. In fact, the sector reinvests, on average, about 20% of their revenue into the search for new treatments and cures.

This is one of the highest levels of investment intensity among all industries in America.

The biopharmaceutical industry’s investment in R&D is approximately three times the entire budget of the National Institutes of Health. And the sector as a whole accounts for more than 18% of all domestic R&D funded by U.S. businesses - the single largest share among R&D-intensive industry sectors.

Member Companies

PhRMA’s member companies are committed to the search for new treatments and cures, leading the charge to beat devasting diseases like COVID-19. They are pioneers in innovation, ushering in a new era of treatments for patients. A list of our member companies is below.